NEPHROLOGY DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Nephrology Drugs Market Size and Trends

Global nephrology drugs market is estimated to be valued at USD 17.2 Bn in 2024 and is expected to reach USD 26.9 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031. Growing prevalence of kidney diseases such as chronic kidney disease, diabetes mellitus, and polycystic kidney disease globally can drive the nephrology drugs market growth during the forecast period.

To learn more about this report, request sample copy

The market is witnessing growth due to increasing investment by leading manufacturers for the development of novel drugs to treat kidney disorders. Furthermore, rising awareness about kidney diseases and availability of various treatment options can offer opportunities for the market players. However, stringent regulatory frameworks for the approval of nephrology drugs can hamper the market growth.

Market Driver – Increasing Prevalence of Kidney Diseases

Global nephrology drugs market is witnessing significant growth due to increasing incidence and prevalence of various kidney diseases across the world. Kidney diseases have become a major global health problem with an increasing trend observed in both developed and developing countries. According to the data published by WHO, chronic kidney disease affected approximately 10% of the world's population in 2020. The major risk factors attributing to kidney diseases include rising cases of obesity, prevalence of diabetes and hypertension, aging population, and growing environmental pollutants. These factors have triggered various forms of chronic and end-stage kidney diseases, resulting in increased need for dialysis treatment and kidney transplant procedures. Rising patient pool suffering from conditions like chronic kidney failure, glomerulonephritis, polycystic kidney disease, and others has boosted demand for varied nephrology drugs used for both acute and chronic management of symptoms. Pharmaceutical companies have channeled more resources towards development of novel drugs for effective treatment of kidney disorders. For instance, according to an article published by International Society of Nephrology (ISN), there has been rise in prevalence of kidney diseases with more than 850 million people worldwide affected by the disease. Chronic Kidney Disease (CKD) affects approximately 10.4% of men and 11.8% of women globally, while acute kidney injury (AKI) annually impacts 13.3 million people, a figure that underscores the acute nature of the problem. Rising prevalence of kidney diseases not only poses a substantial burden on healthcare systems but also underscores the urgent need for enhanced public awareness, early detection strategies, and accessible treatment options to mitigate the escalating impact of this silent epidemic.

Growing Geriatric Population

Rising geriatric population worldwide, who are more susceptible to developing kidney diseases, can drive the market growth. Older adults often have coexisting conditions such as hypertension, cardiovascular diseases, and diabetes which further elevate the risk. Moreover, aging physiology makes the kidneys less efficient over time. According to the data from United Nations, there were over 727 million people aged 65 years and above globally in 2020, which accounted for nearly 9% of the world's population. This geriatric demographic is expected to double to 1.5 billion by 2050. Aged individuals require more vigilant nephrology care and long term pharmacotherapy using multiple drugs. With rising life expectancy, there will be increase in consumption of nephrology medications by elderly population. Expanding aging demographics coupled with associated complex medical conditions can drive the market growth.